Abstract 599TiP
Background
Hepatocyte growth factor receptor (HGF)/mesothelial-epithelial transition (MET) pathway activation is known as an oncogenic driver in NSCLC. MET overexpression has been reported to be associated with worse clinical outcomes of NSCLCs. In China, the current second-line standard of care for EGFR/ALK/ROS1/METex14m-wildtype NSCLC with MET overexpression is mono-chemotherapy or immune checkpoint inhibitor, but with limited efficacy. Preclinically, the synergistic effect of savolitinib and docetaxel was tested in both CDX and PDX models. A phase I study explored the safety and tolerability of savolitinb plus docetaxel in advanced solid tumors. This study (NCT05777278) aims to explore the efficacy and safety of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression.
Trial design
This is an ongoing, phase I/II, pilot, open-label, single arm, single center, interventional study. Eligible patients will be those diagnosed with MET overexpression, EGFR/ALK/ROS1/METex14m-wildtype NSCLC in advanced stages and not treated with MET inhibitors. MET overexpression is defined as IHC 3+ in ≥50% of tumor cells. Patients will receive docetaxel (60 mg/m2, ivgtt, q3w) and savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID) after signing informed consent. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, other discontinuation criterion is met, or study completion. The primary objectives include assessing the efficacy by Objective Response Rate (ORR) and the safety and tolerability profile of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression. The secondary objective is to assess the efficacy through Progression-Free Survival (PFS), Duration of Response (DoR), Disease Control Rate (DCR), Overall Survival (OS), 12 months OS rate using investigator assessments according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). The exploratory objective is to assess efficacy in the MET-high (in 90% tumor cells IHC 3+) population.
Clinical trial identification
NCT05777278, 03/17/2023.
Legal entity responsible for the study
The authors.
Funding
AstraZeneca, China and Hutchison Whampoa, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract